ReviewCNS drugs2022
Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments.
Review in CNS drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of disease-modifying oral drugs in treatment of relapsing-remitting multiple sclerosis: systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Article
- Real-world safety assessment of ublituximab: a pharmacovigilance analysis based on the FDA adverse event reporting system.International journal of clinical pharmacy · 2025Article
- Predictors of Ability to Work in Multiple Sclerosis.CPT: pharmacometrics & systems pharmacology · 2025Article
- Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy.Neurodegenerative disease management · 2025Article
- Microbiota-Derived SCFAs in Multiple Sclerosis: From Immune Priming to Neurodegeneration.Molecular neurobiology · 2025Review
- Personalized therapy in multiple sclerosis: an Italian Delphi consensus.Journal of neurology · 2025Article
- Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.Journal of neurology · 2025Review
- Eomesodermin-expressing CD4 Th cells and association with multiple sclerosis progression and brain atrophy.Brain communications · 2025Article
- Current Practices, Challenges, and Future Directions in Multiple Sclerosis Management in Sub-Saharan Africa.International journal of MS care · 2024Article
- Computational Analysis of S1PR1 SNPs Reveals Drug Binding Modes Relevant to Multiple Sclerosis Treatment.Pharmaceutics · 2024Article
- Electrical stimulation of the vagus nerve ameliorates inflammation and disease activity in a rat EAE model of multiple sclerosis.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Single-Cell Sequencing Combined with Transcriptome Sequencing Constructs a Predictive Model of Key Genes in Multiple Sclerosis and Explores Molecular Mechanisms Related to Cellular Communication.Journal of inflammation research · 2024Article
- From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment.Biomedicines · 2023Review
- Differential impact of environmental factors on systemic and localized autoimmunity.Frontiers in immunology · 2023Review
- Omics approaches to understanding the efficacy and safety of disease-modifying treatments in multiple sclerosis.Frontiers in genetics · 2023Review
- Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment.Frontiers in neurology · 2022Review
- Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccination.Therapeutic advances in neurological disorders · 2022Article
- Immune response in ofatumumab treated multiple sclerosis patients after SARS-CoV-2 vaccination.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis treatment made substantial headway during the last two decades with the implementation of therapeutics with new modes of action and routes of application. We are now in the situation that second-generation molecules, approved since 2018, are on the market, characterized by reduced side effects using a more tailored therapeutic approach. Diroximel fumarate is a second-generation fumarate with reduced gastrointestinal side effects. Moreover, several novel, selective, sphingosine-1-phosphate receptor modulators with reduced off-target effects have been developed; namely siponimod, ozanimod, and ponesimod; all oral formulations. B-cell-targeted therapies such as ocrelizumab, given intravenously, and since 2021 ofatumumab, applied subcutaneously, complement the spectrum of novel therapies. The glycoengineered antibody ublituximab is the next anti-CD20 therapy about to be approved. Within the next years, oral inhibitors of Bruton's tyrosine kinase, currently under investigation in several phase III trials, may be licensed for multiple sclerosis. Those developments currently offer an individualized multiple sclerosis therapy, targeting patient needs with substantial effects on relapses, disability progression, and implications for daily life. In this up-to-date review, we provide a holistic overview about novel developments of the therapeutic landscape and upcoming approaches for multiple sclerosis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.